Scarica l'app Stockscreener
26.45
0.39%
0.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$26.34
Aprire:
$26.78
Volume 24 ore:
567.56K
Relative Volume:
0.12
Capitalizzazione di mercato:
$19.64B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-82.66
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
+8.55%
1M Prestazione:
+28.61%
6M Prestazione:
+12.43%
1 anno Prestazione:
+165.49%
Intervallo 1D:
$25.81
$26.91
Intervallo di 1 settimana:
$25.00
$28.62
Portata 52W:
$8.88
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
26.45 | 18.86B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.93 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.52 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.16 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire
Is Summit Therapeutics Inc. a good long term investmentMassive portfolio appreciation - jammulinksnews.com
What drives Summit Therapeutics Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com
What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com
Meet the Biotech Stock That Rocketed 775% Higher - AOL.com
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance
3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World
Summit Therapeutics Inc. Stock Analysis and ForecastFree Predictions - Autocar Professional
Published on: 2025-07-19 02:49:19 - jammulinksnews.com
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire
Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World
Summit Therapeutics: Not Entirely Positive HARMONi Data And Partnership Rumors (SMMT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Stockholders to Reach Out - ACCESS Newswire
10 Stocks Exploding Higher: Bitcoin Miners Dominate the List - Insider Monkey
how summit therapeutics inc. stock performs during market volatilityAnalyst Grade Signals - Newser
Summit Therapeutics Jumps 16% On Heavy Volume As Technicals Signal Bullish Breakout - AInvest
Summit Therapeutics Inc (SMMT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Summit Therapeutics Explodes 12%: Legal Probe Ignites Volatility Amid Regulatory Crosshairs - AInvest
Summit Therapeutics Soars 16.5% Amid Regulatory Crossroads and Whale Activity - AInvest
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug - MSN
What makes Summit Therapeutics Inc. stock price move sharplyFree Predictions - Newser
H.C. Wainwright Keeps Their Buy Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Why Summit Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - FinancialContent
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential - MSN
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
Where are the Opportunities in (SMMT) - news.stocktradersdaily.com
10 Stocks Going Wild - Insider Monkey
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal - Insider Monkey
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance
Pomerantz LLP Investigates Claims Against Summit Therapeutics Inc. - AInvest
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.62%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):